Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as epratuzumab, hLL2, veltuzumab, IMMU-106, hA20, humanized CD20, epratuzumab-tetraxetan, IMMU-102
90Y-hLL2 · 3 trials · 23 indications
safety will be assessed by monitoring lab results and adverse events, which will be assessed every 3 months for up to 2 years.
| Arm | Type | Description |
|---|---|---|
| veltuzumab | EXPERIMENTAL | veltuzumab is a humanized CD20 antibody administered subcutaneously in this study. |
| multi | EXPERIMENTAL | escalating in increments of 2.5 mCi/m2 |
| Name | Type | Description |
|---|---|---|
| veltuzumab | BIOLOGICAL | veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks. |
| 90Y-hLL2 | BIOLOGICAL | weekly dosing for either 2 or 3 weeks |
Inclusion Criteria: * Histologically confirmed diagnosis of CD20 positive chronic lymphocytic leukemia (CLL) * Either previously untreated or relapsed * Measurable disease (at least one lesion \> 1.5 cm for NHL, or ALC \> 5,000 for CLL) see full protocol for additional criteria Exclusion Criteria:...
90Y-hLL2 is an investigational monoclonal antibody being studied for the treatment of non-Hodgkin lymphoma (NHL), including B-cell NHL. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
90Y-hLL2 is being developed by Gilead Sciences, Inc. (NASDAQ: GILD). The drug is an investigational monoclonal antibody in Phase 1 clinical development for the treatment of non-Hodgkin lymphoma.
90Y-hLL2 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 safety study of 90Y-hLL2 in patients with non-Hodgkin lymphoma has been completed.
90Y-hLL2 has one completed clinical trial, NCT00421395, a Phase 1 safety study in patients with non-Hodgkin lymphoma, including B-cell NHL. The study enrolled 59 participants and was conducted in France and Germany.
90Y-hLL2 is a radiolabeled form of the monoclonal antibody hLL2, where the antibody is conjugated to the radioisotope yttrium-90. The drug is being studied for its potential to deliver radiation directly to cancer cells in non-Hodgkin lymphoma.